Literature DB >> 16931060

Washout of heme-containing proteins dramatically improves tetrazolium-based infarct staining.

Kelly R Pitts1, Ann Stiko, Bernard Buetow, Fred Lott, Ping Guo, Duke Virca, Christopher F Toombs.   

Abstract

INTRODUCTION: Methods to determine infarct size following ischemia-reperfusion injury include gross staining with triphenyltetrazolium chloride (TTC) and perfusion of colored dyes to demarcate the non-ischemic zone. Infarcted tissue (INF) can typically appear a mottled tan to brownish color, making a border between INF and TTC-positive tissue difficult to discern. Previous work in our lab indicated that following TTC staining, prolonged washing of thick sections dramatically sharpened this boundary.
METHODS: Adult rats underwent 30 min ischemia via LAD ligation and reperfusion/recovery over 24 h. Hearts were then harvested, thick-sectioned, and stained with TTC. Stained sections were stored in PBS at 4 degrees C for up to 3 weeks.
RESULTS: Histology on thin sections from infarcted hearts fixed directly after harvest revealed extensive hemorrhage within the INF. However, this hemorrhage is washed out when hearts are stored in PBS for 3 weeks. SDS-PAGE of PBS samples taken at 1, 2, and 3 weeks showed a low molecular weight band appearing over time. Peptide sequencing revealed the presence of several proteins including the heme-containing proteins (HCPs) hemoglobin, cytochrome c, and myoglobin. The loss of HCPs from thick sections to PBS corresponded with the blanching of the previously mottled INF within each section. HPLC analysis of these samples confirmed the loss of HCPs contributes to INF whitening. Further, analysis of infarct size values derived from heart slices with or without HCPs showed a significant decrease in measurement error when values were derived from slices without HCPs. DISCUSSION: These data suggest that HCPs in the heart tissue contribute to the non-uniform and discolored appearance of the INF, and that washout of these proteins produces an INF more easily distinguished from neighboring non-infarcted tissue. This method greatly reduces the error associated with infarct measurements and improves the analysis of the effects of drug treatments and other interventions designed to impact ischemia reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931060     DOI: 10.1016/j.vascn.2006.06.005

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  5 in total

1.  The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.

Authors:  Offir Ertracht; Esti Liani; Noa Bachner-Hinenzon; Orit Bar-Am; Luba Frolov; Elena Ovcharenko; Huda Awad; Shany Blum; Yaron Barac; Tamar Amit; Dan Adam; Moussa Youdim; Ofer Binah
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

2.  Advanced methods for quantification of infarct size in mice using three-dimensional high-field late gadolinium enhancement MRI.

Authors:  Steffen Bohl; Craig A Lygate; Hannah Barnes; Debra Medway; Lee-Anne Stork; Jeanette Schulz-Menger; Stefan Neubauer; Jurgen E Schneider
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-13       Impact factor: 4.733

3.  Optical projection tomography permits efficient assessment of infarct volume in the murine heart postmyocardial infarction.

Authors:  X Zhao; J Wu; C D Gray; K McGregor; A G Rossi; H Morrison; M A Jansen; G A Gray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-12       Impact factor: 4.733

4.  Refined approach for quantification of in vivo ischemia-reperfusion injury in the mouse heart.

Authors:  Steffen Bohl; Debra J Medway; Jeanette Schulz-Menger; Jurgen E Schneider; Stefan Neubauer; Craig A Lygate
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-10-09       Impact factor: 4.733

5.  The differential effects of FTY720 on functional recovery and infarct size following myocardial ischaemia/reperfusion.

Authors:  Derick van Vuuren; Erna Marais; Sonia Genade; Amanda Lochner
Journal:  Cardiovasc J Afr       Date:  2016 Nov/Dec       Impact factor: 1.167

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.